Bending The Cost Curve: Harvard's Cutler Says Rx Can Play A Big Role
This article was originally published in RPM Report
Health care cost trends may not be so bad after all, former Obama advisor writes in New England Journal of Medicine. Prescription drugs can help, he writes-but not entirely in the way industry would hope.
You may also be interested in...
There are multiple political strategies playing out in Washington on health care reform that will directly impact the biopharma industry. In the end biopharma will trade margins for volume. The RPM Report makes predictions on what will make it into the final health reform bill.
The withdrawal of Tom Daschle from consideration as HHS Secretary means there won't be a single focus for health care policy during the upcoming health care reform debate. Can two powerful Democratic legislators and the Obama budget team fill the void?
As the presidential race heats up, health care executives say they have many reasons to be excited--and nervous. BCG reviews an industry-wide survey on the implications of the candidates' health care proposals for the pharma and device industries.